Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30737479 | 0.86 | HPGDS (0.53) | MAPK1PSMD14LCKLMNAKDM4E | |
| SCHEMBL23474092 | 0.84 | LCK (0.41) | MAPK1POLBLCKLMNAKDM4E | |
| SCHEMBL30737193 | 0.78 | LMNA (0.51) | MAPK1LMNAKDM4EL3MBTL1CA12 | |
| SCHEMBL30737363 | 0.76 | HPGDS (0.51) | PSMD14LCKLMNAMEN1KMT2A | |
| SCHEMBL19808827 | 0.75 | HRH3 (0.48) | MAPK1POLBLMNAKDM4EL3MBTL1 | |
| SCHEMBL30737249 | 0.75 | HPGDS (0.50) | PSMD14LCKLMNAMEN1KMT2A | |
| SCHEMBL30737273 | 0.74 | PLK1 (0.47) | MAPK1LCKLMNAKDM4EL3MBTL1 | |
| SCHEMBL24313800 | 0.73 | LMNA (0.46) | MAPK1LMNAKDM4EL3MBTL1CA12 | |
| SCHEMBL23474167 | 0.72 | LMNA (0.41) | MAPK1POLBLCKLMNAKDM4E | |
| SCHEMBL1797972 | 0.72 | HSPB1 (0.54) | MAPK1LMNAKDM4EL3MBTL1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165843-A1 | USE AND PHARMACEUTICAL COMPOSITION OF PHENYLISOXAZOLYL METHYLENE-NAPHTHALENE-ETHER DERIVATIVES | GANNEX PHARMA CO LTD (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230165843-A1 | USE AND PHARMACEUTICAL COMPOSITION OF PHENYLISOXAZOLYL METHYLENE-NAPHTHALENE-ETHER DERIVATIVES | GANNEX PHARMA CO LTD (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20220388997-A1 | COMPOUNDS FOR MODULATING ACTIVITY OF FXR AND USES THEREOF | GANNEX PHARMA CO., LTD. (CN) | 2022-12-08 | — | — | US | disclosed |
| CN-112898289-B | Compounds for modulating FXR activity and uses thereof | 甘莱制药有限公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-112891348-B | Use of phenyl isoxazolyl methylene-naphthalene-ether derivatives and pharmaceutical compositions | 甘莱制药有限公司 | 2022-06-28 | — | — | CN | disclosed |
| WO-2021109713-A1 | USE AND PHARMACEUTICAL COMPOSITION OF PHENYLISOXAZOLYL METHYLENE-NAPHTHALENE-ETHER DERIVATIVES | GANNEX PHARMA CO., LTD. (CN) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021108974-A1 | COMPOUNDS FOR MODULATING ACTIVITY OF FXR AND USES THEREOF | GANNEX PHARMA CO., LTD (CN) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021109712-A1 | COMPOUNDS FOR MODULATING ACTIVITY OF FXR AND USES THEREOF | GANNEX PHARMA CO., LTD. (CN) | 2021-06-10 | — | — | WO | disclosed |
| CN-112898289-A | Compounds for modulating FXR activity and uses thereof | 甘莱制药有限公司 | 2021-06-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165843-A1 | USE AND PHARMACEUTICAL COMPOSITION OF PHENYLISOXAZOLYL METHYLENE-NAPHTHALENE-ETHER DERIVATIVES | VIM, CYP3A7, HAVCR2 | MAPK1 4004/4885PSMD14 1587/4885POLB 1280/4885 |
| US-20220388997-A1 | COMPOUNDS FOR MODULATING ACTIVITY OF FXR AND USES THEREOF | NR1H4, FXR1, FXR2 | MAPK1 1217/4885PSMD14 4643/4885POLB 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.